U.S. Stock Futures Steady as AI, Rate Concerns Weigh 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
RBA Hikes Interest Rate to 4.60% as Inflation Risks Rise 
Asian Stocks Fall as Oil Surge, Bond Yields and AI Concerns Hit Markets 
Oil Prices Rise as Iran Holds Firm on Strait of Hormuz Deal 
RBA Set for September Rate Hike as Inflation Stays High 
Asian Currencies Mixed as Yen Weakens, RBA Hike Looms 
Asian Currencies Weaken as Dollar, Oil Prices Rise 
US Stocks Face Jobs, Inflation Test as Fed Rate Hike Bets Rise 
XRP Price Targets $1.70 as Bullish Momentum Builds 
Hong Kong Home Prices Stabilize in August After July Decline 
Gold Holds Near Seven-Week Low as Fed Rate Hike Bets Rise 
Asian Chip Stocks Tumble as OpenAI Safety Pause Sparks AI Growth Concerns 
U.S. Stock Futures Fall as Iran, Oil and AI Risks Rattle Markets 
UK Housebuilder Stocks Surge on New First-Time Buyer Loan Scheme 
Asian Stocks Fall as Bond Yields and Oil Prices Surge 
Gold Slides Below $4,300 as Oil Surge Fuels Fed Rate Hike Bets 
Add as a preferred source on Google
Activist investor Starboard Value has acquired a $1 billion stake in Pfizer to push for strategic changes in the U.S. pharmaceutical giant. This investment comes as Pfizer contends with declining sales of its COVID-19 vaccines and treatments, underwhelming sales for its RSV vaccine, and failed clinical trials for an obesity medication.
Former Pfizer Executives to Aid Starboard’s Efforts
Starboard has approached Ian Read, Pfizer’s CEO until 2019, and Frank D’Amelio, who served as CFO until 2021. Both former executives are interested in helping Starboard steer the company toward renewed growth.
Stock Price Decline Post-COVID Success
Albert Bourla, who became CEO in 2019, was key in partnering with BioNTech to develop Pfizer's COVID-19 vaccine. However, as pandemic demand wanes, the company’s stock has plummeted from approximately $41 to $28.58 as of last Friday, reflecting concerns over weakened vaccine demand and disappointing new product launches.
Aggressive Acquisitions Draw Scrutiny
Since 2020, Pfizer has made over $70 billion in acquisitions, including major deals like Seagen for $43 billion, Biohaven for $13 billion, Arena for $6 billion, Global Blood Therapeutics for $5 billion, and Trillium for $2 billion. The acquisitions have raised investor concerns, especially regarding GBT’s sickle cell drug, which faced market withdrawal due to severe side effects and discontinuation of related studies.
Starboard’s History of Corporate Overhauls
Known for pushing changes in major companies like News Corp, Salesforce, and Match Group, Starboard Value's influence could lead to significant shifts in Pfizer's strategic direction.
The Wall Street Journal first reported Starboard’s Pfizer stake. Neither Pfizer nor Starboard has officially commented on the investment or potential next steps.
